TouchNEUROLOGY caught up with Roger McIntyre (University Toronto, Ontario, Canada) to discuss psychedelics, and in particular psilocybin-based therapies, and their potential in the treatment of mood disorders.
Questions
1. Please could you give us a brief overview of psilocybin and its action on serotonergic (5-HT) pathways? (0:04)
2. Which conditions are most likely to benefit from psilocybin therapy? (0:48)
3. What are the major challenges in bringing psilocybin-based products to the market? (1:57)
4. Could you tell us a little about the products you are working with and the current research activities? (3:18)
5. What will be the next steps in the development of psilocybin-based therapies? (4:38)
Speaker Disclosure: Roger McIntyre has acted as a consultant and/or received research support from Lundbeck, Janssen, Shire, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Minerva, Intra-Cellular Pharmaceuticals, Stanley Medical Research Institute, and CIHR/GACD/National Natural Science Foundation of China. He is CEO of Champignon, which acquired the Canadian Rapid Treatment Centre of Excellence.
Support: Interview and filming supported by Touch Medical Media.
